Dong-A ST (Vice Chairman Kang Soo-hyoung) held a ceremony for the ‘Declaration of CP Reinforcement and ISO 37001 Introduction’ during the meeting of its sales division at the KT Daejeon Human Resource Development Center in Seo-gu, Daejeon on November 22.

The declaration ceremony was held to establish a fair and ethical culture of compliance and a global anti-bribery management system.

Around 580 employees attended the ceremony, including President Min Jang-seong and the company’s sales general manager and sales branch managers. All of the employees present read the CP compliance message and the voluntary compliance pledge signed by President Min Jang-seong to put into practice ethical management.

Dong-A ST introduced the CP and established compliance guidelines and operating standards for the first time in the industry in 2007. After establishing the CP team in 2010, the organization was expanded to CP management in 2014, and the President was appointed as the compliance manager. In recognition of these efforts, the company received the ‘AA’ grade in the CP rating of the Fair Trade Commission in 2015.

The newly introduced ISO 37001 is an anti-bribery management system designed to prevent and discourage illegal exchanges of money and acts of bribery, and is operated according to the standards set by the International Organization for Standardization (ISO).

As Dong-A ST is subject to the first round of certification, the company will be certified after a seven-month-long certification review lasting from December of this year to June 2018.

During his welcome speech, Dong-A ST President Min Jang-seong said, “We have now introduced the anti-bribery management system of international standards in line with our growth as a global healthcare company and our new vision and spirit of challenge, along with the fair trade compliance program which has become mandatory. Through the fair trade compliance program and the anti-bribery management system that we are declaring today, I hope that Dong-A ST will grow into a great company and become a global healthcare leader."

Dong-A ST also held a co-promotion ceremony for ‘Edarbi’, an anti-hypertensive drug, at the sales division meeting that followed the declaration ceremony. Marketing executives and stakeholders of Korea Takeda Pharmaceutical also attended the ceremony to strengthen cooperation between the two companies and make a firm pledge to achieve their sales goals.

Dong-A ST signed the agreement with Korea Takeda Pharmaceutical for joint sales and marketing of Edarbi, an ARB-based anti-hypertensive drug that is proven to be highly effective in lowering blood pressure and has an excellent safety profile. In the Phase III clinical trials for patients with stage 1 and 2 hypertension, Edarbi demonstrated a superior 24-hour BP lowering effect compared to Olmesartan and Valsartan.